Association between plasma xanthine oxidoreductase activity and in-hospital outcomes in patients with stable coronary artery disease after percutaneous coronary intervention
Fig 2
Percent changes in plasma XOR activity day 1, day 2 and day 3 from baseline in patients with and without composite in-hospital adverse events.